

Calibrant Biosystems, a leader in the field of proteomics-based drug and biomarker discovery and development, today announced the appointments of James Hawkins, PhD, MBA, Bethany Mancilla, MBA, and Douglas Swirsky, CPA, CFA, to its newly-formed Business Advisory Board. Dr. Michael Salgaller, Chief Operating Officer, said "We are excited and honored to have Dr. Hawkins, Ms. Mancilla, and Mr. Swirsky associated with our Company at this important stage in our history. Their stellar talents and successful track records bring a wide range of talents to address the complex, challenging issues facing early-stage biotechnology companies. We look forward to their contributions as our Company continues to grow and develop its Gemini™ proteomics technology and oncology drug and biomarker pipeline."

James Hawkins, PhD, MBA, is a Managing Director at FOCUS, LLC (Washington, DC), an investment bank providing an array of services specifically addressing the needs of emerging growth and middle market businesses. Dr. Hawkins' career has centered on the strategic and operational aspects of founding, growing, and exiting emerging businesses – including tenures as President and CEO of five early stage biotechnology companies. He has played key roles in a wide range of business development and financial transactions –including the acquisition and sale of companies and the solicitation of equity and debt financing.

Bethany Mancilla, MBA is Vice President of Business Development and Licensing for PharmAthene Inc., (Annapolis, MD), a biopharmaceutical company developing vaccines and biotechnology countermeasures for a range of potential biological and chemical weapons. In her current capacity, she is primarily responsible for biopharmaceutical partnering initiatives and transactions. Ms. Mancilla came to PharmAthene after nearly a decade at Gene Logic, where she served in a number of executive positions, including Vice President of Strategic Alliances. While there, she negotiated multi-million alliances with companies such as Pfizer, Roche, Wyeth, Lilly, Abbott, and Merck Serono.

Douglas Swirsky, CPA, CFA, is Chief Financial Officer for GenVec, Inc. (Gaithersburg, MD), a biopharmaceutical company developing novel gene-based therapeutics and vaccines. Prior to joining GenVec, Mr. Swirsky served as Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus, and held the same position at Legg Mason before Stifel Financial acquired Legg Mason's Capital Markets business in 2005. An expert in capital formation for biotechnology companies, his expertise also encompasses positions in public accounting and consulting.

Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug and biomarker discovery and development. With an initial focus on oncology therapeutics, Calibrant is leveraging the Gemini(TM) platform for the development of first-in-class therapeutics and biomarkers for cancer and other major unmet medical needs.

Contact

Dr. Michael Salgaller
Chief Operating Officer
Calibrant Biosystems
910 Clopper Road, Suite 220N
Gaithersburg, MD 20878
Voice: 301-977-7900